Yuanjin Zhang | Medicine | Best Researcher Award

Dr. Yuanjin Zhang | Medicine | Best Researcher Award

Peking University Third Hospital | China

Dr. Yuanjin Zhang is a distinguished neurologist and chief physician at Peking University Third Hospital, recognized for her pioneering work in neurotherapeutics, neurodegeneration, and digital medicine. Educated and trained at Peking University Health Science Center, she combines strong clinical expertise with innovative research in amyotrophic lateral sclerosis, neuropathic pain, and AI-driven healthcare technologies. Her professional journey bridges academic medicine and industry, where she has led numerous multi-center clinical and translational projects focused on diabetic neuropathy, stroke, and cognitive disorders. Dr. Zhang’s research interests encompass neurological and vascular sciences, digital biomarkers, mHealth platforms, and precision neurorehabilitation. She possesses advanced skills in clinical data analytics, bioinformatics, AI algorithm development, and translational neurotechnology, supported by extensive NIH and NSFC-funded collaborations. Her contributions to journals such as BMC Neurology, Scientific Reports, and JMIR MHealth UHealth highlight her global impact on digital neurotherapeutics. As a reviewer for leading journals and an active member of national neurology and neuroscience societies, she promotes interdisciplinary collaboration across China’s medical and research communities. Honored for her leadership and scientific innovation, Dr. Zhang continues to shape the future of neurology through AI-enabled clinical care and patient-centered neurotechnology, embodying excellence in research, mentorship, and translational impact.

Profile: ORCID

Featured Publications

Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Dr. Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Dr. Vahid Rashedi 👨‍⚕️, an esteemed Assistant Professor of Gerontology at the University of Social Welfare and Rehabilitation Sciences 🇮🇷, has made outstanding global contributions in aging, cognition, and psychogeriatrics 🌍🧠. With a Ph.D. in Gerontology (2017) 🎓 and extensive editorial duties across high-impact journals 📚, he’s actively involved as a Senior Collaborator with the Global Burden of Disease Project at IHME, University of Washington 🇺🇸. Recognized as a Top 1% scientist by Stanford University in 2024 🏅, he combines academic excellence, innovation, and impactful research. His interdisciplinary work spans gerontology, rehabilitation, mental health, and cognitive science, cementing his status as a global leader in aging research 🌐💡.

Profile

Education 🎓

Dr. Rashedi began his academic path with a Bachelor’s and Master’s degree in Rehabilitation Sciences 🎓🦾, focusing on geriatric care and assistive technology. He earned his Ph.D. in Gerontology with distinction in 2017 🥇, building expertise in psychogeriatrics, mental health, and cognitive decline. His academic training was rooted in interdisciplinary frameworks linking medicine, psychology, and social work 🔬💬. This diverse education empowered him to bridge clinical insights with research, enabling innovative health solutions for elderly populations 👵👴. He complements formal education with global scientific memberships and ongoing collaborations with prestigious institutes, such as IHME 🌎, emphasizing lifelong learning and cutting-edge research.

Experience 👨‍🏫

Dr. Rashedi has over a decade of rich academic and research experience, currently serving as Assistant Professor at the University of Social Welfare and Rehabilitation Sciences 🏫. Since 2019, he has been a Senior Collaborator at IHME, University of Washington, contributing to the Global Burden of Disease project 📊🌐. He has authored 126 indexed journal articles 📑, published a book 📖, and holds four patents, including rehabilitation innovations like the vibrating ankle-foot orthosis 🦿. He is a prolific editorial board member and associate editor for over 10 international journals 📘🖋️. His work in psychogeriatrics and cognition has garnered global recognition, highlighting his leadership and mentoring roles 👨‍🏫🏅.

Awards & Recognitions 🏅

Dr. Rashedi is recognized globally for his scientific excellence, notably ranked in the Top 1% of scientists worldwide by Stanford University in 2024 🌟📈. He holds editorial roles in Frontiers, CGJ, and the Journal of Gerontology, reflecting scholarly esteem 📚. He is a trusted reviewer for numerous high-impact journals and was honored with national and international awards 🥇. His patented inventions in geriatric rehabilitation demonstrate a blend of innovation and clinical value 💡🏥. His GSA, APA, and ISTAART memberships validate his international standing 👏🌐. These honors underscore his unwavering dedication to improving elderly lives through evidence-based science and collaboration 🤝

Research Interests 🔬

Dr. Rashedi’s research delves into psychogeriatrics, mental health, and cognitive disorders in aging populations 🧠👴. As part of the Global Burden of Disease team at IHME 🌍, he contributes to global health analytics, shaping international aging policies 📊. His innovations include assistive devices with therapeutic functions, bridging technology and clinical rehabilitation 🛠️⚙️. With 63 research projects and over 26,000 citations 🔍📈, his scholarly output is extensive and impactful. He leads investigations on dementia, geriatric depression, and cognitive resilience, supported by his roles in editorial boards and scientific societies 🧬📘. His mission is to translate research into real-world health solutions for aging communities 🌟🩺.

Publications 

Marcelo Luis Berthier | Neuroscience| Best Researcher Award

Prof. Marcelo Luis Berthier | Neuroscience| Best Researcher Award

 

Unversidad de Málaga, Spain

Profile

Education

Marcelo Luis Berthier obtained his degree in Medicine (1972-1976) and completed residency training in Neurosurgery (1977-1980), later specializing in Neurology (1980). He served as a staff neurologist at the Institute of Neurological Research, FLENI, Buenos Aires, Argentina (1980-1989), before becoming a research fellow in the Department of Neurology at Clinic Hospital of Barcelona, Spain (1989-1990). From 1991 to 2000, he was a staff neurologist and physician in charge of the Behavioural Neurology Unit at the Clinic University Hospital of Malaga. He earned a PhD in Neuroscience (cum laude) from the University of Malaga and coordinated the Group of Behavioural Neurology and Dementia of the Spanish Neurological Society (2004-2006). In 2004, he founded and directed the Unit of Cognitive Neurology and Aphasia at the Centro de Investigaciones Médico-Sanitarias, University of Malaga, leading it until 2023. Additionally, he served as the director of the Consolidated Research Group on Cognitive Neuroscience: Aphasia and Related Disorders (UNCA, C-12) at the Instituto de Investigación Biomédica de Málaga (IBIMA – Plataforma BIONAND).

Work experience

Dr. Marcelo L. Berthier Torres has led and contributed to several groundbreaking research projects in cognitive neurology and aphasia. As a co-investigator, he participated in the Telerehabilitation in Aphasia project (2021-2023), which evaluated the effectiveness of telerehabilitation compared to face-to-face therapy and identified predictive biomarkers of response, funded by the Junta de Andalucía. He also served as the principal investigator for a study on the efficacy of combined treatment with donepezil, intensive rehabilitation, and transcranial direct current stimulation in chronic post-stroke aphasia (2016-2019), funded by the Instituto de Salud Carlos III. Additionally, he has contributed to the Proyectos de Generación de Conocimiento “Frontera”, an initiative under the FEDER Andalucía 2014-2020 program, which investigates brain biomarkers for individualized treatment approaches in chronic post-stroke aphasia

Areas of Research

Dr. Marcelo L. Berthier Torres has made significant contributions to the treatment of post-stroke aphasia and speech-language disorders. He conducted the first open-label and randomized, placebo-controlled, double-blind trials investigating the use of cognitive-enhancing drugs (donepezil and memantine) alone and in combination with standard aphasia therapy or intensive language-action therapy (ILAT) in chronic post-stroke aphasia. His pioneering studies stimulated international research on aphasia pharmacotherapy, leading to clinical translation. Today, donepezil and memantine, alone or combined with therapy, are widely used off-label for post-stroke aphasia and language disturbances associated with neurodegenerative disorders like Alzheimer’s disease and primary progressive aphasia.

Publication

  • Revisiting the boundaries of different altered accents profiles

    Cortex
    2025-03 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Ignacio Moreno-Torres; Jo Verhoeven; Guadalupe Dávila
  • Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

    CNS Drugs
    2023-07 | Journal article
    CONTRIBUTORS: Guadalupe Dávila; María José Torres-Prioris; Diana López-Barroso; Marcelo L. Berthier
  • Pharmacotherapy for post-stroke aphasia: what are the options?

    Expert Opinion on Pharmacotherapy
    2023-07-24 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Guadalupe Dávila
  • Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia

    Brain Structure and Function
    2023-05-31 | Journal article
    CONTRIBUTORS: Diana López-Barroso; José Paredes-Pacheco; María José Torres-Prioris; Guadalupe Dávila; Marcelo L. Berthier
  • Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia

    Aphasiology
    2022-11-02 | Journal article
    CONTRIBUTORS: Marcelo L. Berthier; Daniel Santana-Moreno; Álvaro Beltrán-Corbellini; Juan C. Criado-Álamo; Lisa Edelkraut; Diana López-Barroso; Guadalupe Dávila; María José Torres-Prioris